KALY Publishes Cannabis Extract COPD Treatment Study Report

DALLAS, March 22, 2019 /PRNewswire/ — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published the research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process. The report details the study method and the significance of the study. The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests.

“These preliminary studies were designed to begin assessment of the relative efficacy of NCMB-1 compound on pulmonary of in the AGM previously treated to induce a fixed level of airway fibrosis. The overall results demonstrate that NCMB-1 improved airway function as measured by increased tidal volume, increased airway flow and hence decreased airway resistance and increased respiration rate.”

“Given the in vitro studies previously conducted in cultured human pulmonary epithelial cells, the role of anti-inflammatory agents and

... read more at: https://www.prnewswire.com/news-releases/kaly-publishes-cannabis-extract-copd-treatment-study-report-300816903.html